What is the new drug for hypersensitivity pneumonitis?
•
4 min read
While antigen avoidance remains the cornerstone of treatment, a significant advancement for patients with chronic fibrotic hypersensitivity pneumonitis (HP) is the use of the antifibrotic medication nintedanib. This development marks an important shift from primarily using immunosuppressants, offering a targeted approach to slow down lung scarring associated with progressive fibrosis.
